Pharma Marketletter - Positive new data for Merck & Co’s Singulair.
Results presented at the 13th European Respiratory Society Annual Congress in Vienna, Austria, demonstrated that young children whose asthma is triggered by upper respiratory infections experience fewer asthma attacks when treated with Merck & Co’s Singulair (montelukast sodium) compared with …
Related Results
Popular prescription drugs
Gilead Names John W. Madigan to Board and Merck Announces US Label Change for…
Positive new data for Merck & Co’s Singulair.
For allergic rhinitis, two drugs found equivalent.(Pulmonary Medicine)(Drug o…
Drug patent expiration list. (Rx/Generic Drugs).(Brief Article)
Want to read the whole article? You can purchase it here. It’s quick and easy.
